Tim Cronin

Tim Cronin

Auto-generated profile, based on publicly available information

Tim Cronin

School of Medicine and Health, University College Cork, Cork, Ireland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2024 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Open access
PDF file
RKRuth Kieran
Ruth Kieran
MHMaeve Hennessy
Maeve Hennessy
KCKate Coakley
Kate Coakley
HOHazel O’sUllivan
Hazel O’sUllivan
TCTim Cronin
Tim Cronin
SOSeamus O'Reilly
Seamus O'Reilly
A combination of improvements in patient survival, increasing treatment duration, and the development of more expensive agents has led to a doubling of per-capita spending on cancer medicines in Ireland (2008–2018). Despite this, access to new drugs is poor in comparison to other EU countries. We examine methods to optimise oncology drug spending to facilitate access to newer anticancer agents. Key targets for spending optimisation (biosimilar use, clinical trials and expanded access programs, waste reduction, avoidance of futile treatment, and altered drug scheduling) were identified through an exploratory analysis. A structured literature search was performed, with a focus on articles relevant to the Irish Healthcare system, supplemented by reports from statutory bodies. At the present time, EMA-approved agents are available once approved by the NCPE. Optimising drug costs occurs through guideline-based practice and biosimilar integration, the latter provides €80 million in cost savings annually. Access to novel therapies can occur via over 50 clinical trials and 28 currently available expanded access programmes. Additional strategies include reversion to weight-based immunotherapy dosing, potentially saving €400,000 per year in our centre alone, vial sharing, and optimisation of treatment schedules. A variety of techniques are being employed by oncologists to optimise costs and increase access to innovation for patients. Use of biosimilars, drug wastage, and prescribing at end of life should be audited as key performance indicators, which may lead to reflective practice on treatment planning. Such measures could further optimise oncology drug expenditure nationally facilitating approval of new agents.

28 May 2024 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Open access
PDF file
TCTimothy K. Cronin
Timothy K. Cronin
CRCian Ronayne
Cian Ronayne
NONiamh O’dOnovan
Niamh O’dOnovan
EMEimear McGuinness
Eimear McGuinness
KCKatie Cooke
Katie Cooke
SOSeamus O'Reilly
Seamus O'Reilly
Background: Expanded access programs (EAPs) allow cancer patients with unmet clinical need to obtain access to pre-authorisation treatments. There is no standardised process for implementing these programs nationally, and real-world data on their impact is lacking. Aims: This study aimed to evaluate the prevalence of such EAPs and their impact in a cancer centre. Methods: Data relating to adult cancer patients treated via EAPs from 2011 to 2021 in three Cork university hospitals was collated. Descriptive statistics were employed to get an overview of the impact these programs currently have on cancer care provision. Results: We identified 193 patients who accessed EAPs during the study period, availing of 33 separate drugs for a total of 50 different cancer indications. The prevalence of EAP usage was shown to have been trending upwards in recent years with a total of 189 programs being accessed throughout the period. Drugs provided were from a number of different anti-cancer drug classes, particularly targeted therapies (n = 18) and immune checkpoint inhibitors (n = 17). Cancers from a wide range of both solid and liquid tumour types were treated with EAP drugs, and patients treated were from across a broad spectrum of ages (26–82, SD 11.99). Conclusions: EAPs have an increasing role in accessing novel cancer therapies in our community and by extension nationally. Equity of EAP access would be facilitated by a national registry of available agents which we have established. Assessment of their benefits and toxicities would be enhanced by the requirement for a real-world database as a condition of EAP approval.

13 March 2026 in Kidney International Case Reports
Verified
Journal Article
Open access
TCTimothy Kevin Cronin
Timothy Kevin Cronin
CCCliona Cowhig
Cliona Cowhig
SKSally Kemp
Sally Kemp
TWTamara Wanigasekera
Tamara Wanigasekera
EMEoghan Molloy
Eoghan Molloy
SMSarah Margaret Moran
Sarah Margaret Moran

12 April 2023 in Research Square
Verified
Preprint
Open access
PDF file
TCTimothy K Cronin
Timothy K Cronin
CRCian Ronayne
Cian Ronayne
NONiamh O’donovan
Niamh O’donovan
EMEimear McGuinness
Eimear McGuinness
KCKatie Cooke
Katie Cooke
SOSeamus O'Reilly
Seamus O'Reilly
Purpose Expanded access programs (EAPs) allow patients with cancer who have unmet clinical needs to obtain access to pre-authorisation treatments. There is no standardised process or registry for implementing these programs nationally and real world data on their impact is lacking. We evaluated their prevalence and impact in a cancer centre.Methods Data relating to adult cancer patients treated via EAPs from 2011 to 2021 in three Cork university hospitals was collated. Descriptive statistics were employed to get an overview of the impact these programs currently have on cancer care provision.Results We identified 193 patients who accessed EAPs during the study period, availing of 33 separate drugs for a total of 50 different cancer indications. The prevalence of EAP usage was shown to have been trending upwards in recent years with a total of 189 programs being accessed throughout the period. Drugs provided were from a number of different anti-cancer drug classes, particularly targeted therapies (n = 18) and immune checkpoint inhibitors (n = 17). Cancers from a wide range of both solid and liquid tumour types were identified as having been treated with EAP drugs and patients treated were from across a broad spectrum of ages (26–82, SD:11.99).Conclusion EAPs have an increasing role in access to novel cancer therapies in our community and by extension nationally. Equity of EAP access would be facilitated by a national registry of available agents which we have now established. Assessment of their benefits and toxicities would be enhanced by the requirement for a real world data base as a condition of EAP approval.

1 April 2023 in Mesentery and Peritoneum
Verified
Journal Article
Open access
PDF file
YBYasir Bashir
Yasir Bashir
MAMahmoud Musa Hussein Al-Awaysheh
Mahmoud Musa Hussein Al-Awaysheh
BMBernadette McGovern
Bernadette McGovern
ARAbidur Rahman
Abidur Rahman
JOJosh Olanyi
Josh Olanyi
PNPaul Neary
Paul Neary
Background: Government-funded health systems are the hallmarks of welfare states. They always suffer from over-burden and are underfunded. This results in painful waiting lists and long clinics. In order to reduce the suffering of patients attending surgical outpatient clinics, the innovative initiative of telephone clinics was taken five years ago. This study was conducted to assess success and find areas or groups requiring attention. Methods: A retrospective analysis of a prospectively maintained database was done. The first 1,000 patients given an appointment from January 2015 in the telephone clinic were found using the Hospital In-Patient Enquiry (HIPE) reporting system. Characteristics regarding age, gender, and procedure performed were recorded and the effect of these characteristics on attendance and outcome of the clinic was analysed to find any relation. Results: The mean age of the patients in the study was 50.6 years with 477 males and 523 females comprising 47.7% and 52.3% respectively. The largest group was of 402 given appointments to outline their endoscopic findings followed by 198 patients who underwent laparoscopic procedures like appendicectomies, hernias, and adhesiolysis, etc. The analysis found that out of the patients who attended the telephone clinic, 71.5% were discharged after the first appointment. There was no relation found between attendance, discharge based on gender P=0.51 and 0.60 respectively. However, a statistically significant relation was found between attendance, discharges, and “Millennial generation” P=0.029 and 0.002 respectively. Conclusions: Telephone clinics are a safe, cost-effective, convenient and patient-friendly alternative to conventional clinics. They were used frequently and effectively during coronavirus disease 2019 (COVID-19) pandemic to reduce transmission.

20 October 2023 in Annals of Oncology
Verified
Journal Article
Closed access
RKR. Kieran
R. Kieran
KCKathryn E Coakley
Kathryn E Coakley
TCT. Cronin
T. Cronin
CWCatherine Sarah Weadick
Catherine Sarah Weadick
BMB. Macanovic
B. Macanovic
SOS. O'Reilly
S. O'Reilly